



DRUG PRIOR AUTHORIZATION COMMITTEE AGENDA

Date:
December 15, 2022

Time:
10:00am – 3:00pm (CST)

Location:
Howerton Building, Room 202
615 Howerton Court
Jefferson City, MO 65109
OR WebEx

Additional Meeting Details

The December 15th DPAC meeting will have both in-person and virtual attendance options. Due to strict capacity limits, public attendance will be based on a first come/first serve sign-up, with a limit of **1 individual per organization**. Those unable to join in-person may listen in/provide public comment via Webex. Individuals wishing to attend in-person must contact **Carmen Burton** at Carmen.M.Burton@dss.mo.gov or call (573) 751-6961.

[Join Webex Meeting](#)

Meeting number (access code): 2462 161 1951
Meeting password: EqnPhdBK425

Join from a Video System/Application
Dial 24621611951@stateofmo.webex.com
Or dial 173.243.2.68 and enter the meeting number

Join from a Mobile Device (attendees only)
[1-650-479-3207](tel:1-650-479-3207) Call-in toll number (US/Canada)

[* Click HERE for Meeting Documents *](#)

Opening Statements/Updates

10:00 – 10:05	Welcome, Announcements and Introductions	Chairperson
10:05 – 10:15	Minutes Review	Discussion/Approval
10:15 – 10:35	Nominations and Election of Drug Prior Authorization Committee Chair	Josh Moore
10:35 – 10:45	Pharmacy Program/Budget Update	Elizabeth Short
10:45 – 11:00	Prior Authorization Process and Update	Elizabeth Sissom

Old Business

11:00 – 11:15	Implementation Schedule – Criteria for Previously Approved Clinical Edits, Step Therapies and PA's	Josh Moore
---------------	--	------------

New Business

11:15 – 11:30	Proposed Actions - New Drug/Product Review (See Website and Attached Summary)	Olivia Rush
	i. Open Access	
	ii. Clinical Edit/Step Therapy	
	iii. Resource List	
	iv. PDL Agents	
	v. Prior Authorization	

Clinical and Fiscal Edit Review

11:30 – 12:15	<u>Existing Criteria</u>	Josh Moore
	i. Aduhelm Clinical Edit	
	ii. Antipsychotics, 1st Generation (Typical) Clinical Edit	

- iii. Benzodiazepine, Select Oral Clinical Edit
- iv. Butalbital Combinations without Codeine Clinical Edit
- v. Corlanor Clinical Edit
- vi. Empaveli Clinical Edit
- vii. HBV Nucleotide Analog Reverse Transcriptase Inhibitors Fiscal Edit
- viii. High Risk Therapies Clinical Edit
- ix. Kerendia Clinical Edit
- x. Morphine Milligram Equivalent (MME) Accumulation Clinical Edit
- xi. Non-Oral Contraceptives Fiscal Edit
- xii. Oxazolidinone Fiscal Edit
- xiii. Pompe Disease Clinical Edit
- xiv. Selzentry Clinical Edit
- xv. Transmucosal Immediate Release Fentanyl (TIRF) Clinical Edit
- xvi. Verquvo Clinical Edit

New Criteria or Revision of Existing Criteria

- i. Camzyos Clinical Edit
- ii. Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Modulators Clinical Edit
- iii. Opioids, Short Acting Clinical Edit
- iv. Skysona Clinical Edit
- v. Xenpozyme Clinical Edit
- vi. Ztalmy Clinical Edit
- vii. Zynteglo Clinical Edit

Resource List Edit Review

12:15 – 12:45 Existing Criteria - none Josh Moore

New Criteria or Revision of Existing Criteria

- i. Antipsychotics - 2nd Generation (Atypical) Depot Agents
- ii. Antipsychotics - 2nd Generation (Atypical) Oral & Transdermal Agents

Break

12:45 – 1:00 Lunch

Preferred Drug List Edit Review

1:00 – 2:00 Existing Criteria Josh Moore

- i. Alzheimer's Agents, AChEIs and NMDA Receptor Antagonists & Combinations PDL Edit
- ii. Antiemetics, 5-HT₃ and NK₁ Injectables PDL Edit
- iii. Antiemetics, 5-HT₃, NK₁ and Other Select Non-Injectables PDL Edit
- iv. Anti-Migraine, Serotonin (5-HT₁) Receptor Agonists PDL Edit
- v. Anti-Parkinsonism, MAO-B Inhibitors PDL Edit
- vi. Anti-Parkinsonism, Non-Ergot Dopamine Agonists PDL Edit
- vii. Cyclin-Dependent Kinase (CDK) 4/6 Inhibitors PDL Edit
- viii. Glucagon Agents PDL Edit
- ix. Hereditary Angioedema Agents PDL Edit
- x. NSAIDs PDL Edit
- xi. Opioid Emergency Reversal Agents PDL Edit
- xii. Opioids, Long Acting PDL Edit
- xiii. Somatostatin Analogs PDL Edit
- xiv. Vesicular Monoamine Transporter 2 (VMAT2) Inhibitors PDL Edit

New Criteria or Revision of Existing Criteria

- i. Antiandrogenic Agents PDL Edit
- ii. Anticonvulsants, Dravet Syndrome PDL Edit
- iii. Anti-Migraine, Alternative Oral Agents PDL Edit
- iv. Antiplatelet Agents PDL Edit
- v. Antiretroviral Therapy (ART) PDL Edit
- vi. Calcitonin Gene-Related Peptide (CGRP) Inhibitors PDL Edit
- vii. Fibromyalgia Agents PDL Edit
- viii. GI Motility Agents, Chronic PDL Edit
- ix. Mitogen-activated Extracellular Kinase Inhibitors (MEKi) & B-raf Kinase Inhibitors (BRAFi) PDL Edit
- x. Neuropathic Pain Agents PDL Edit
- xi. Opioid & Select Alcohol Dependence Agents PDL Edit
- xii. Sedative Hypnotics PDL Edit
- xiii. Skeletal Muscle Relaxants PDL Edit
- xiv. Tramadol-Like Agents PDL Edit

Program Utilization Information – Conduent Update

2:00 – 2:30	Reports	Jennifer Colozza
	i. Call Center Statistics	
	ii. “Top 25” Drugs by Cost/Claims	

Other Business/Closing Comments

2:30 – 2:50	Other Business
-------------	----------------

Informal comments will be accepted from members of the audience at various points in the agenda. Times noted are approximate, agenda may move more quickly.

Next Meeting: April 18, 2023

Meeting location and attendance options subject to change

Howerton Building, Room 202
615 Howerton Court
Jefferson City, MO 65109

Public attendance may be limited

Webex

Motion to Close: *I move that this meeting be closed, and that all records and votes pertaining to and/or resulting from this closed meeting be closed, under Section 610.021 Subsection (14),(5) RSMo for proceedings required pursuant to a disciplinary order concerning medical, psychiatric, psychological, or alcoholism or drug dependency diagnosis or treatment of specific licensees.*